1. March WA, Moore VM, Willson KJ, Phillips DI, Norman RJ, Davies MJ. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod. 2010;25(2): 544-551. doi:10.1093/humrep/dep399
2. Sadeghi HM, Adeli I, Calina D, et al. Polycystic ovary syndrome: a comprehensive review of pathogenesis, management, and drug repurposing. Int J Mol Sci. 2022;23(2):583. doi:10.3390/ijms23020583
3. Alesi S, Ee C, Moran LJ, Rao V, Mousa A. Nutritional supplements and complementary therapies in polycystic ovary syndrome. Adv Nutr. 2022;13(4):1243-1266. doi:10.1093/advances/nmab141
4. Chang S, Dunaif A. Diagnosis of polycystic ovary syndrome: which criteria to use and when? Endocrinol Metab Clin North Am. 2021;50(1):11-23. doi:10.1016/j.ecl.2020.10.002
5. Zhao H, Zhang J, Cheng X, Nie X, He B. Insulin resistance in polycystic ovary syndrome across various tissues: an updated review of pathogenesis, evaluation, and treatment. J Ovarian Res. 2023;16(1):9. doi:10.1186/s13048-022-01091-0
6. Thomson RL, Spedding S, Buckley JD. Vitamin D in the aetiology and management of polycystic ovary syndrome. Clin Endocrinol (Oxf). 2012; 77(3):343-350. doi:10.1111/j.1365-2265.2012.04434.x
7. Holick MF. Vitamin D: important for prevention of osteoporosis, cardiovascular heart disease, type 1 diabetes, autoimmune diseases, and some cancers. South Med J. 2005;98(10):1024-1027. doi:10.1097/01.SMJ. 0000140865.32054.DB
8. Li HW, Brereton RE, Anderson RA, Wallace AM, Ho CK. Vitamin D deficiency is common and associated with metabolic risk factors in patients with polycystic ovary syndrome. Metabolism. 2011;60(10):1475-1481. doi:10.1016/j.metabol.2011.03.002
9. Firouzabadi Rd, Aflatoonian A, Modarresi S, Sekhavat L, MohammadTaheri S. Therapeutic effects of calcium & vitamin D supplementation in women with PCOS. Complement Ther Clin Pract. 2012;18(2):85-88. doi:10.1016/j.ctcp.2012.01.005
10. Apridonidze T, Essah PA, Iuorno MJ, Nestler JE. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2005;90(4):1929-1935. doi:10. 1210/jc.2004-1045
11. Szczuko M, Skowronek M, Zapalowska-Chwyc M, Starczewski A. Quantitative assessment of nutrition in patients with polycystic ovary syndrome (PCOS). Rocz Panstw Zakl Hig. 2016;67(4):419-426.
12. Asemi Z, Esmaillzadeh A. DASH diet, insulin resistance, and serum hs-CRP in polycystic ovary syndrome: a randomized controlled clinical trial. Horm Metab Res. 2015;47(3):232-238. doi:10.1055/s-0034-1376990
13. Chutia H, Lynrah KG. Association of serum magnesium deficiency with insulin resistance in type 2 diabetes mellitus. J Lab Physicians. 2015;7(2): 75-78. doi:10.4103/0974-2727.163131
14. Rajeswari G, Veerabhadrudu B, Suresh E. Study of magnesium levels in polycystic ovarian syndrome. Int J App Res. 2016;2(3):610-613. doi:10. 7439/ijasr.v2i2.2870
15. Kotsa K, Yavropoulou MP, Anastasiou O, Yovos JG. Role of vitamin D treatment in glucose metabolism in polycystic ovary syndrome. Fertil Steril. 2009;92(3):1053-1058. doi:10.1016/j.fertnstert.2008.07.1757
16. Yildizhan R, Kurdoglu M, Adali E, et al. Serum 25-hydroxyvitamin D concentrations in obese and non-obese women with polycystic ovary syndrome. Arch Gynecol Obstet. 2009;280(4):559-563. doi:10.1007/s00404- 009-0958-7
17. Li HW, Brereton RE, Anderson RA, Wallace AM, Ho CK. Vitamin D deficiency is common and associated with metabolic risk factors in patients with polycystic ovary syndrome. Metabolism. 2011;60(10):1475-1481. doi:10.1016/j.metabol.2011.03.002
18. Pittas AG, Lau J, Hu FB, Dawson-Hughes B. The role of vitamin D and calcium in type 2 diabetes. A systematic review and meta-analysis. J Clin Endocrinol Metab. 2007;92(6):2017-2029. doi:10.1210/jc.2007-0298
19. Maestro B, Molero S, Bajo S, Dávila N, Calle C. Transcriptional activation of the human insulin receptor gene by 1,25-dihydroxyvitamin D(3). Cell Biochem Funct. 2002;20(3):227-232. doi:10.1002/cbf.951
20. Wekker V, van Dammen L, Koning A, et al. Long-term cardiometabolic disease risk in women with PCOS: a systematic review and meta-analysis. Hum Reprod Update. 2020;26(6):942-960. doi:10.1093/humupd/ dmaa029
21. Wild RA, Rizzo M, Clifton S, Carmina E. Lipid levels in polycystic ovary syndrome: systematic review and meta-analysis. Fertil Steril. 2011;95(3): 1073-9.e11. doi:10.1016/j.fertnstert.2010.12.027
22. Krentowska A, Kowalska I. Metabolic syndrome and its components in different phenotypes of polycystic ovary syndrome. Diabetes Metab Res Rev. 2022;38(1):e3464. doi:10.1002/dmrr.3464
23. Rocha MP, Marcondes JA, Barcellos CR, et al. Dyslipidemia in women with polycystic ovary syndrome: incidence, pattern and predictors. Gynecol Endocrinol. 2011;27(10):814-819. doi:10.3109/09513590.2010.508852
24. Keskin Kurt R, Okyay AG, Hakverdi AU, et al. The effect of obesity on inflammatory markers in patients with PCOS: a BMI-matched case-control study. Arch Gynecol Obstet. 2014;290(2):315-319. doi:10.1007/s00404-014-3199-3
25. Herlihy AC, Kelly RE, Hogan JL, O’Connor N, Farah N, Turner MJ. Polycystic ovary syndrome and the peripheral blood white cell count. J Obstet Gynaecol. 2011;31(3):242-244. doi:10.3109/01443615.2011.553693
26. Phelan N, O’Connor A, Kyaw Tun T, et al. Leucocytosis in women with polycystic ovary syndrome (PCOS) is incompletely explained by obesity and insulin resistance. Clin Endocrinol (Oxf). 2013;78(1):107-113. doi:10.1111/j.1365-2265.2012.04454.x
27. Kabil Kucur S, Gozukara I, Aksoy A, et al. How medical treatment affects mean platelet volume as a cardiovascular risk marker in polycystic ovary syndrome? Blood Coagul Fibrinolysis. 2015;26(8):862-865. doi:10.1097/MBC.0000000000000229